Recent insights in the therapeutic management of patients with gastric cancer

Digestive and Liver Disease

Volumn 48, Issue 9, 2016, Pages 984-994

  de Mestier, Louis ^a   Lardière Deguelte, Sophie ^a   Volet, Julien ^a   Kianmanesh, Reza ^a   Bouché, Olivier ^a  

^a SERVICE DE DERMATOLOGIE   (France)

Author keywords

Chemotherapy; Gastric neoplasms; Peritoneal carcinomatosis; Prognosis; Radiation therapy; Surgery; Target therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MAMMALIAN TARGET OF RAPAMYCIN; RAMUCIRUMAB; SCATTER FACTOR RECEPTOR; TRASTUZUMAB; MONOCLONAL ANTIBODY;

ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; COMPUTER ASSISTED TOMOGRAPHY; CYTOLOGY; DRUG TREATMENT FAILURE; HUMAN; LAPAROSCOPIC SURGERY; LAPAROSCOPY; METASTASIS; MOLECULARLY TARGETED THERAPY; PERIOPERATIVE PERIOD; PERITONEUM LAVAGE; PRIORITY JOURNAL; REVIEW; STOMACH CANCER; SYSTEMIC THERAPY; DIAGNOSTIC IMAGING; DISEASE MANAGEMENT; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); STOMACH NEOPLASMS; X-RAY COMPUTED TOMOGRAPHY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE MANAGEMENT; HUMANS; LAPAROSCOPY; MOLECULAR TARGETED THERAPY; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STOMACH NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; TRASTUZUMAB;

EID: 84964754566     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2016.04.010     Document Type: Review

References (155)

1. [1] Ferlay, J., Shin, H.-R., Bray, F., et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer 127 (2010), 2893–2917.
2. [2] Ferlay, J., Steliarova-Foucher, E., Lortet-Tieulent, J., et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. European Journal of Cancer 49 (2013), 1374–1403.
3. [3] De Angelis, R., Sant, M., Coleman, M.P., et al. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5—a population-based study. Lancet Oncology 15 (2014), 23–34.
4. [4] Henson, D.E., Dittus, C., Younes, M., et al. Differential trends in the intestinal and diffuse types of gastric carcinoma in the United States, 1973–2000: increase in the signet ring cell type. Archives of Pathology and Laboratory Medicine 128 (2004), 765–770.
5. [5] Wu, H., Rusiecki, J.A., Zhu, K., et al. Stomach carcinoma incidence patterns in the United States by histologic type and anatomic site. Cancer Epidemiology, Biomarkers and Prevention 18 (2009), 1945–1952.
6. [6] Baiocchi, G.L., Tiberio, G.A., Minicozzi, A.M., et al. A multicentric Western analysis of prognostic factors in advanced, node-negative gastric cancer patients. Annals of Surgery 252 (2010), 70–73.
7. [7] Messager, M., Lefevre, J.H., Pichot-Delahaye, V., et al. The impact of perioperative chemotherapy on survival in patients with gastric signet ring cell adenocarcinoma: a multicenter comparative study. Annals of Surgery 254 (2011), 684–693 discussion 693.
8. [8] Waddell, T., Verheij, M., Allum, W., et al. Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 24:Suppl. 6 (2013), vi57–vi63.
9. [9] Sun, W., Han, X., Wu, S., et al. Endoscopic resection versus surgical resection for early gastric cancer: a systematic review and meta-analysis. Medicine, 94, 2015, e1649.
10. [10] Song, K.Y., Kim, J.J., Kim, S.N., et al. Staging laparoscopy for advanced gastric cancer: is it also useful for the group which has an aggressive surgical strategy?. World Journal of Surgery 31 (2007), 1230–1235.
11. [11] Power, D.G., Schattner, M.A., Gerdes, H., et al. Endoscopic ultrasound can improve the selection for laparoscopy in patients with localized gastric cancer. Journal of the American College of Surgeons 208 (2009), 173–178.
12. [12] Hori, Y., SAGES Guidelines Committee. Diagnostic laparoscopy guidelines: this guideline was prepared by the SAGES Guidelines Committee and reviewed and approved by the Board of Governors of the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES), November 2007. Surgical Endoscopy 22 (2008), 1353–1383.
13. [13] Japanese Gastric Cancer Association, 3rd English edition Japanese classification of gastric carcinoma, vol. 14, 2011, Gastric Cancer, 101–112.
14. [14] Gastric Cancer, NCCN clinical practice guidelines in oncology. Version 3. 2015, National Comprehensive Cancer Network NCCN.org [consulted 17.04.15].
15. [15] Cotte, E., Peyrat, P., Piaton, E., et al. Lack of prognostic significance of conventional peritoneal cytology in colorectal and gastric cancers: results of EVOCAPE 2 multicentre prospective study. European Journal of Surgical Oncology 39 (2013), 707–714.
16. [16] Bando, E., Yonemura, Y., Takeshita, Y., et al. Intraoperative lavage for cytological examination in 1,297 patients with gastric carcinoma. American Journal of Surgery 178 (1999), 256–262.
17. [17] Bentrem, D., Wilton, A., Mazumdar, M., et al. The value of peritoneal cytology as a preoperative predictor in patients with gastric carcinoma undergoing a curative resection. Annals of Surgical Oncology 12 (2005), 347–353.
18. [18] Kodera, Y., Nakanishi, H., Yamamura, Y., et al. Prognostic value and clinical implications of disseminated cancer cells in the peritoneal cavity detected by reverse transcriptase-polymerase chain reaction and cytology. International Journal of Cancer 79 (1998), 429–433.
19. [19] Leake, P.-A., Cardoso, R., Seevaratnam, R., et al. A systematic review of the accuracy and utility of peritoneal cytology in patients with gastric cancer. Gastric Cancer 15:Suppl. 1 (2012), S27–S37.
20. [20] Wang, J.-Y., Lin, S.-R., Lu, C.-Y., et al. Gastric cancer cell detection in peritoneal lavage: RT-PCR for carcinoembryonic antigen transcripts versus the combined cytology with peritoneal carcinoembryonic antigen levels. Cancer Letters 223 (2005), 129–135.
21. [21] Dalal, K.M., Woo, Y., Kelly, K., et al. Detection of micrometastases in peritoneal washings of gastric cancer patients by the reverse transcriptase polymerase chain reaction. Gastric Cancer 11 (2008), 206–213.
22. [22] Kodera, Y., Nakanishi, H., Ito, S., et al. Quantitative detection of disseminated free cancer cells in peritoneal washes with real-time reverse transcriptase-polymerase chain reaction: a sensitive predictor of outcome for patients with gastric carcinoma. Annals of Surgery 235 (2002), 499–506.
23. [23] Yano, M., Tsujinaka, T., Shiozaki, H., et al. Appraisal of treatment strategy by staging laparoscopy for locally advanced gastric cancer. World Journal of Surgery 24 (2000), 1130–1135 discussion 1135-6.
24. [24] Mezhir, J.J., Shah, M.A., Jacks, L.M., et al. Positive peritoneal cytology in patients with gastric cancer: natural history and outcome of 291 patients. Annals of Surgical Oncology 17 (2010), 3173–3180.
25. [25] Kuramoto, M., Shimada, S., Ikeshima, S., et al. Extensive intraoperative peritoneal lavage as a standard prophylactic strategy for peritoneal recurrence in patients with gastric carcinoma. Annals of Surgery 250 (2009), 242–246.
26. [26] Memon, M.A., Khan, S., Yunus, R.M., et al. Meta-analysis of laparoscopic and open distal gastrectomy for gastric carcinoma. Surgical Endoscopy 22 (2008), 1781–1789.
27. [27] Haverkamp, L., Weijs, T.J., van der Sluis, P.C., et al. Laparoscopic total gastrectomy versus open total gastrectomy for cancer: a systematic review and meta-analysis. Surgical Endoscopy 27 (2013), 1509–1520.
28. [28] Dikken, J.L., van Sandick, J.W., Allum, W.H., et al. Differences in outcomes of oesophageal and gastric cancer surgery across Europe: outcomes of oesophageal and gastric cancer surgery across Europe. British Journal of Surgery 100 (2013), 83–94.
29. e ed., 2010, Springer, Chicago, IL.
30. [30] Sobin, L.H., Gospodarowicz, M.K., Wittekind, C., TNM classification of malignant tumours. 7th ed. 2009, 2010, Wiley-Blackwell, Chichester, West Sussex, UK/Hoboken, NJ 310 p.
31. [31] Chu, X., Yang, Z.-F., Impact on survival of the number of lymph nodes resected in patients with lymph node-negative gastric cancer. World Journal of Surgical Oncology, 13, 2015 http://www.wjso.com/content/13/1/192 [cite 16.02.16].
32. [32] Sasako, M., Principles of surgical treatment for curable gastric cancer. Journal of Clinical Oncology 21:Suppl (2003), 274s–275s.
33. [33] Zhang, J., Zhou, Y., Jiang, K., et al. Evaluation of the seventh AJCC TNM staging system for gastric cancer: a meta-analysis of cohort studies. Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine 35 (2014), 8525–8532.
34. [34] Japanese Gastric Cancer Association Registration Committee, Maruyama, K., Kaminishi, M., Hayashi, K.-I., et al. Gastric cancer treated in 1991 in Japan: data analysis of nationwide registry. Gastric Cancer: Official Journal of the International Gastric Cancer Association and Japanese Gastric Cancer Association 9 (2006), 51–66.
35. [35] Mocellin, S., Nitti, D., Lymphadenectomy extent and survival of patients with gastric carcinoma: a systematic review and meta-analysis of time-to-event data from randomized trials. Cancer Treatment Reviews 41 (2015), 448–454.
36. [36] El-Sedfy, A., Dixon, M., Seevaratnam, R., et al. Personalized surgery for gastric adenocarcinoma: a meta-analysis of D1 versus D2 lymphadenectomy. Annals of Surgical Oncology 22 (2015), 1820–1827.
37. [37] Jiang, L., Yang, K.-H., Guan, Q.-L., et al. Survival and recurrence free benefits with different lymphadenectomy for resectable gastric cancer: a meta-analysis. Journal of Surgical Oncology 107 (2013), 807–814.
38. [38] Jiang, L., Yang, K.-H., Chen, Y., et al. Systematic review and meta-analysis of the effectiveness and safety of extended lymphadenectomy in patients with resectable gastric cancer: outcome of extended lymphadenectomy in resectable gastric cancer. British Journal of Surgery 101 (2014), 595–604.
39. [39] Seevaratnam, R., Bocicariu, A., Cardoso, R., et al. A meta-analysis of D1 versus D2 lymph node dissection. Gastric Cancer 15:S1 (2012), 60–69.
40. [40] Memon, M.A., Subramanya, M.S., Khan, S., et al. Meta-analysis of D1 versus D2 gastrectomy for gastric adenocarcinoma. Annals of Surgery 253 (2011), 900–911.
41. [41] Degiuli, M., Sasako, M., Ponti, A., Morbidity and mortality in the Italian Gastric Cancer Study Group randomized clinical trial of D1 versus D2 resection for gastric cancer. British Journal of Surgery 97 (2010), 643–649.
42. [42] Wang, Z., Systematic review of D2 lymphadenectomy versus D2 with para-aortic nodal dissection for advanced gastric cancer. World Journal of Gastroenterology, 16, 2010, 1138.
43. [43] Chen, X.-Z., Hu, J.-K., Zhou, Z.-G., et al. Meta-analysis of effectiveness and safety of D2 plus para-aortic lymphadenectomy for resectable gastric cancer. Journal of the American College of Surgeons 210 (2010), 100–105.
44. [44] Wang, W., Zhang, X., Shen, C., et al. Laparoscopic versus open total gastrectomy for gastric cancer: an updated meta-analysis. PLOS ONE, 9, 2014, e88753.
45. [45] Piessen, G., Messager, M., Leteurtre, E., et al. Signet ring cell histology is an independent predictor of poor prognosis in gastric adenocarcinoma regardless of tumoral clinical presentation. Annals of Surgery 250 (2009), 878–887.
46. [46] Zhang, C.-D., Zeng, Y.-J., Li, H.-W., et al. Neoadjuvant chemotherapy for nonmetastatic esophago-gastric adenocarcinomas: a systematic review and meta-analysis. Cancer Investigation 31 (2013), 421–431.
47. [47] Cunningham, D., Allum, W.H., Stenning, S.P., et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. New England Journal of Medicine 355 (2006), 11–20.
48. [48] Ychou, M., Boige, V., Pignon, J.-P., et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. Journal of Clinical Oncology 29 (2011), 1715–1721.
49. [49] Liao, Y., Yang, Z., Peng, J., et al. Neoadjuvant chemotherapy for gastric cancer: a meta-analysis of randomized, controlled trials: neoadjuvant chemotherapy for gastric cancer. Journal of Gastroenterology and Hepatology 28 (2013), 777–782.
50. [50] Xu, A.-M., Huang, L., Liu, W., et al. Neoadjuvant chemotherapy followed by surgery versus surgery alone for gastric carcinoma: systematic review and meta-analysis of randomized controlled trials. Bathen, T.F., (eds.) PLoS ONE, 9, 2014, e86941.
51. [51] Li, W., Qin, J., Sun, Y.-H., et al. Neoadjuvant chemotherapy for advanced gastric cancer: a meta-analysis. World Journal of Gastroenterology 16 (2010), 5621–5628.
52. [52] Xiong, B., Ma, L., Cheng, Y., et al. Clinical effectiveness of neoadjuvant chemotherapy in advanced gastric cancer: an updated meta-analysis of randomized controlled trials. European Journal of Surgical Oncology 40 (2014), 1321–1330.
53. [53] Sehdev, A., Catenacci, D.V., Perioperative therapy for locally advanced gastroesophageal cancer: current controversies and consensus of care. Journal of Hematology & Oncology, 6, 2013, 66.
54. [54] The Gastrointestinal Cancer Disease Site Group, Knight, G., Earle, C.C., Cosby, R., et al. Neoadjuvant or adjuvant therapy for resectable gastric cancer: a systematic review and practice guideline for North America. Gastric Cancer 16 (2013), 28–40.
55. [55] Glatz, T., Bronsert, P., Schäfer, M., et al. Perioperative platin-based chemotherapy for locally advanced esophagogastric adenocarcinoma: Postoperative chemotherapy has a substantial impact on outcome. European Journal of Surgical Oncology: the Journal of the European Society of Surgical Oncology and the Britain Association of Surgical Oncology 41 (2015), 1300–1307.
56. [56] Luc, G., Gersen-Cherdieu, H., Degrandi, O., et al. Impact of postoperative chemotherapy in patients with locally advanced gastroesophageal adenocarcinoma treated with perioperative chemotherapy strategy. American Journal of Surgery 210 (2015), 15–23.
57. [57] Yang, Y., Yin, X., Sheng, L., et al. Perioperative chemotherapy more of a benefit for overall survival than adjuvant chemotherapy for operable gastric cancer: an updated meta-analysis. Scientific Reports, 5, 2015, 12850.
58. [58] Ferri, L.E., Ades, S., Alcindor, T., et al. Perioperative docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma: a multicenter phase II trial. Annals of Oncology 23 (2012), 1512–1517.
59. [59] Homann, N., Pauligk, C., Luley, K., et al. Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5-fluorouracil, oxaliplatin and docetaxel. International Journal of Cancer 130 (2012), 1706–1713.
60. [60] Takiuchi, H., Hirata, I., Kawabe, S., et al. Immunohistochemical expression of vascular endothelial growth factor can predict response to 5-fluorouracil and cisplatin in patients with gastric adenocarcinoma. Oncology Reports 7 (2000), 841–846.
61. [61] Ott, K., Herrmann, K., Lordick, F., et al. Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study. Clinical Cancer Research 14 (2008), 2012–2018.
62. [62] Piessen, G., Messager, M., Le Malicot, K., et al. Phase II/III multicentre randomised controlled trial evaluating a strategy of primary surgery and adjuvant chemotherapy versus peri-operative chemotherapy for resectable gastric signet ring cell adenocarcinomas – PRODIGE 19 – FFCD1103 – ADCI002. BMC Cancer, 13, 2013, 281.
63. [63] Ott, K., Weber, W.A., Lordick, F., et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. Journal of Clinical Oncology 24 (2006), 4692–4698.
64. [64] Lordick, F., Ott, K., Krause, B.-J., et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncology 8 (2007), 797–805.
65. [65] zum Büschenfelde, C.M., Herrmann, K., Schuster, T., et al. (18)F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial. Journal of Nuclear Medicine 52 (2011), 1189–1196.
66. [66] Kataoka, K., Tokunaga, M., Mizusawa, J., et al. A randomized Phase II trial of systemic chemotherapy with and without trastuzumab followed by surgery in HER2-positive advanced gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301 (Trigger Study). Japanese Journal of Clinical Oncology 45 (2015), 1082–1086.
67. [67] van Hagen, P., Hulshof, M.C.C.M., van Lanschot, J.J.B., et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. New England Journal of Medicine 366 (2012), 2074–2084.
68. [68] Ronellenfitsch, U., Schwarzbach, M., Hofheinz, R., et al. Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus. Cochrane Database of Systematic Reviews, 5, 2013, CD008107.
69. [69] Stahl, M., Walz, M.K., Stuschke, M., et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. Journal of Clinical Oncology 27 (2009), 851–856.
70. [70] Alberts, S.R., Soori, G.S., Shi, Q., et al. Randomized phase II trial of extended versus standard neoadjuvant therapy for esophageal cancer. NCCTG (Alliance) trial N0849. Journal of Clinical Oncology, 31(Suppl), 2013, 4026.
71. [71] Leong, T., Smithers, B.M., Michael, M., et al. TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG). BMC Cancer, 15, 2015, 532.
72. [72] Macdonald, J.S., Smalley, S.R., Benedetti, J., et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. New England Journal of Medicine 345 (2001), 725–730.
73. [73] Smalley, S.R., Benedetti, J.K., Haller, D.G., et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. Journal of Clinical Oncology 30 (2012), 2327–2333.
74. [74] Stiekema, J., Trip, A.K., Jansen, E.P.M., et al. The prognostic significance of an R1 resection in gastric cancer patients treated with adjuvant chemoradiotherapy. Annals of Surgical Oncology 21 (2014), 1107–1114.
75. [75] Hundahl, S.A., Macdonald, J.S., Benedetti, J., et al. Surgical treatment variation in a prospective, randomized trial of chemoradiotherapy in gastric cancer: the effect of undertreatment. Annals of Surgical Oncology 9 (2002), 278–286.
76. [76] Kim, S., Lim, D.H., Lee, J., et al. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. International Journal of Radiation Oncology, Biology, Physics 63 (2005), 1279–1285.
77. [77] Fuchs, C.S., Tepper, J.E., Niedzwiecki, D., et al. Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: intergroup trial CALGB 80101. Journal of Clinical Oncology, 29(Suppl), 2011, 4003.
78. [78] Fiorica, F., Cartei, F., Enea, M., et al. The impact of radiotherapy on survival in resectable gastric carcinoma: a meta-analysis of literature data. Cancer Treatment Reviews 33 (2007), 729–740.
79. [79] Pang, X., Wei, W., Leng, W., et al. Radiotherapy for gastric cancer: a systematic review and meta-analysis. Tumor Biology 35 (2014), 387–396.
80. [80] Huang, Y.-Y., Yang, Q., Zhou, S.-W., et al. Postoperative chemoradiotherapy versus postoperative chemotherapy for completely resected gastric cancer with D2 lymphadenectomy: a meta-analysis. Kozak, K.R., (eds.) PLoS ONE, 8, 2013, e68939.
81. [81] Min, C., Bangalore, S., Jhawar, S., et al. Chemoradiation therapy versus chemotherapy alone for gastric cancer after R0 surgical resection: a meta-analysis of randomized trials. Oncology 86 (2014), 79–85.
82. [82] Dai, Q., Jiang, L., Lin, R.-J., et al. Adjuvant chemoradiotherapy versus chemotherapy for gastric cancer: a meta-analysis of randomized controlled trials. Journal of Surgical Oncology 111 (2015), 277–284.
83. [83] Lee, J., Lim, D.H., Kim, S., et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. Journal of Clinical Oncology 30 (2012), 268–273.
84. [84] Shim, H.-J., Kim, K.-R., Hwang, J.-E., et al. A phase II study of adjuvant S-1/cisplatin chemotherapy followed by S-1-based chemoradiotherapy for D2-resected gastric cancer. Cancer Chemotherapy and Pharmacology, 2016.
85. [85] Sun, P., Xiang, J.-B., Chen, Z.-Y., Meta-analysis of adjuvant chemotherapy after radical surgery for advanced gastric cancer. British Journal of Surgery 96 (2009), 26–33.
86. [86] GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group, Paoletti, X., Oba, K., Burzykowski, T., et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 303 (2010), 1729–1737.
87. [87] Diaz-Nieto, R., Orti-Rodríguez, R., Winslet, M., Post-surgical chemotherapy versus surgery alone for resectable gastric cancer. Cochrane Database of Systematic Reviews, 9, 2013, CD008415.
88. [88] Cao, J., Qi, F., Liu, T., Adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis. Scandinavian Journal of Gastroenterology 49 (2014), 690–704.
89. [89] Zhang, Y.-W., Zhang, Y.-L., Pan, H., et al. Chemotherapy for patients with gastric cancer after complete resection: a network meta-analysis. World Journal of Gastroenterology 20 (2014), 584–592.
90. [90] Sasako, M., Sakuramoto, S., Katai, H., et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. Journal of Clinical Oncology 29 (2011), 4387–4393.
91. [91] Bang, Y.-J., Kim, Y.-W., Yang, H.-K., et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 379 (2012), 315–321.
92. [92] Yu, P., Cheng, X., Du, Y., et al. Significance of MDR-related proteins in the postoperative individualized chemotherapy of gastric cancer. Journal of Cancer Research and Therapeutics 11 (2015), 46–50.
93. [93] Kim, J.-Y., Shin, E., Kim, J.W., et al. Impact of intratumoral expression levels of fluoropyrimidine-metabolizing enzymes on treatment outcomes of adjuvant S-1 therapy in gastric cancer. PLoS ONE, 10, 2015, e0120324.
94. [94] Bajetta, E., Floriani, I., Di Bartolomeo, M., et al. Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. Annals of Oncology 25 (2014), 1373–1378.
95. [95] Tsuburaya, A., Yoshida, K., Kobayashi, M., et al. Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial. Lancet Oncology 15 (2014), 886–893.
96. [96] Yoo, C.H., Noh, S.H., Shin, D.W., et al. Recurrence following curative resection for gastric carcinoma. British Journal of Surgery 87 (2000), 236–242.
97. [97] Maehara, Y., Hasuda, S., Koga, T., et al. Postoperative outcome and sites of recurrence in patients following curative resection of gastric cancer. British Journal of Surgery 87 (2000), 353–357.
98. [98] Wu, C.-W., Lo, S.-S., Shen, K.-H., et al. Incidence and factors associated with recurrence patterns after intended curative surgery for gastric cancer. World Journal of Surgery 27 (2003), 153–158.
99. [99] Yonemura, Y., Bandou, E., Kinoshita, K., et al. Effective therapy for peritoneal dissemination in gastric cancer. Surgical Oncology Clinics of North America 12 (2003), 635–648.
100. [100] Coccolini, F., Cotte, E., Glehen, O., et al. Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials. European Journal of Surgical Oncology 40 (2014), 12–26.
101. [101] Homma, Y., Ushida, S., Yamada, M., et al. Positive peritoneal washing cytology in multiple cavities can predict poor prognosis of advanced gastric cancer patients. Annals of Surgical Oncology 17 (2010), 455–460.
102. [102] Marutsuka, T., Shimada, S., Shiomori, K., et al. Mechanisms of peritoneal metastasis after operation for non-serosa-invasive gastric carcinoma: an ultrarapid detection system for intraperitoneal free cancer cells and a prophylactic strategy for peritoneal metastasis. Clinical Cancer Research 9 (2003), 678–685.
103. [103] Xu, D.-Z., Zhan, Y.-Q., Sun, X.-W., et al. Meta-analysis of intraperitoneal chemotherapy for gastric cancer. World Journal of Gastroenterology 10 (2004), 2727–2730.
104. [104] Yan, T.D., Black, D., Sugarbaker, P.H., et al. A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Annals of Surgical Oncology 14 (2007), 2702–2713.
105. [105] Yu, W., Whang, I., Suh, I., et al. Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer. Annals of Surgery 228 (1998), 347–354.
106. [106] Yonemura, Y., de Aretxabala, X., Fujimura, T., et al. Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer: final results of a randomized controlled study. Hepato-Gastroenterology 48 (2001), 1776–1782.
107. [107] Huang, J.-Y., Xu, Y.-Y., Sun, Z., et al. Comparison different methods of intraoperative and intraperitoneal chemotherapy for patients with gastric cancer: a meta-analysis. Asian Pacific Journal of Cancer Prevention 13 (2012), 4379–4385.
108. [108] Glehen, O., Gilly, F.N., Arvieux, C., et al. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Annals of Surgical Oncology 17 (2010), 2370–2377.
109. [109] Yu, W., Whang, I., Chung, H.Y., et al. Indications for early postoperative intraperitoneal chemotherapy of advanced gastric cancer: results of a prospective randomized trial. World Journal of Surgery 25 (2001), 985–990.
110. [110] Glehen, O., Passot, G., Villeneuve, L., et al. GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: a randomized and multicenter phase III study. BMC Cancer, 14, 2014, 183.
111. [111] Cunningham, D., Starling, N., Rao, S., et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. New England Journal of Medicine 358 (2008), 36–46.
112. [112] Lorenzen, S., Pauligk, C., Homann, N., et al. Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer. British Journal of Cancer 108 (2013), 519–526.
113. [113] Tjwa, E.T.T.L., Holster, I.L., Kuipers, E.J., Endoscopic management of nonvariceal, nonulcer upper gastrointestinal bleeding. Gastroenterology Clinics of North America 43 (2014), 707–719.
114. [114] Lee, H., Min, B.-H., Lee, J.H., et al. Covered metallic stents with an anti-migration design vs. uncovered stents for the palliation of malignant gastric outlet obstruction: a multicenter, randomized trial. American Journal of Gastroenterology, 2015 Available at: http://www.nature.com/ajg/journal/vaop/ncurrent/full/ajg2015286a.html [cite 03.04.16].
115. [115] Park, J.-H., Song, H.-Y., Yun, S.-C., et al. Gastroduodenal stent placement versus surgical gastrojejunostomy for the palliation of gastric outlet obstructions in patients with unresectable gastric cancer: a propensity score-matched analysis. European Radiology, 2015 Available at: http://link.springer.com/10.1007/s00330-015-4106-4 [cite 03.04.16].
116. [116] Mariette, C., Bruyère, E., Messager, M., et al. Palliative resection for advanced gastric and junctional adenocarcinoma: which patients will benefit from surgery?. Annals of Surgical Oncology 20 (2013), 1240–1249.
117. [117] Lasithiotakis, K., Antoniou, S.A., Antoniou, G.A., et al. Gastrectomy for stage IV gastric cancer. A systematic review and meta-analysis. Anticancer Research 34 (2014), 2079–2085.
118. [118] Fujitani, K., Yang, H.-K., Mizusawa, J., et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncology 17 (2016), 309–318.
119. [119] Takemura, N., Saiura, A., Koga, R., et al. Long-term outcomes after surgical resection for gastric cancer liver metastasis: an analysis of 64 macroscopically complete resections. Langenbeck's Archives of Surgery 397 (2012), 951–957.
120. [120] Kodera, Y., Fujitani, K., Fukushima, N., et al. Surgical resection of hepatic metastasis from gastric cancer: a review and new recommendation in the Japanese gastric cancer treatment guidelines. Gastric Cancer 17 (2014), 206–212.
121. [121] Yang, X.-J., Huang, C.-Q., Suo, T., et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Annals of Surgical Oncology 18 (2011), 1575–1581.
122. [122] Wagner, A.D., Unverzagt, S., Grothe, W., et al. Chemotherapy for advanced gastric cancer. Cochrane Database of Systematic Reviews, 2010, CD004064.
123. [123] Wagner, A.D., Grothe, W., Haerting, J., et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. Journal of Clinical Oncology 24 (2006), 2903–2909.
124. [124] Van Cutsem, E., Boni, C., Tabernero, J., et al. Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study. Annals of Oncology 26 (2015), 149–156.
125. [125] Shah, M.A., Janjigian, Y.Y., Stoller, R., et al. Randomized multicenter phase II study of modified docetaxel, cisplatin, and fluorouracil (DCF) versus DCF plus growth factor support in patients with metastatic gastric adenocarcinoma: a study of the US Gastric Cancer Consortium. Journal of Clinical Oncology, 2015.
126. [126] Thuss-Patience, P.C., Kretzschmar, A., Bichev, D., et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer—a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). European Journal of Cancer 47 (2011), 2306–2314.
127. [127] Kang, J.H., Lee, S.I., Lim, D.H., et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. Journal of Clinical Oncology 30 (2012), 1513–1518.
128. [128] Ford, H.E.R., Marshall, A., Bridgewater, J.A., et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncology 15 (2014), 78–86.
129. [129] Hironaka, S., Ueda, S., Yasui, H., et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. Journal of Clinical Oncology 31 (2013), 4438–4444.
130. [130] Guimbaud, R., Louvet, C., Ries, P., et al. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) study. Journal of Clinical Oncology 32 (2014), 3520–3526.
131. [131] Bang, Y.-J., Van Cutsem, E., Feyereislova, A., et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376 (2010), 687–697.
132. [132] Hegewisch-Becker, S., Moorahrend, E., Kroning, H., et al. Trastuzumab (TRA) in combination with different first-line chemotherapies for treatment of HER2-positive metastatic gastric or gastroesophageal junction cancer (MGC): findings from the German noninterventional observational study HerMES. Journal of Clinical Oncology, 30(Suppl), 2012, 4065.
133. [133] Ryu, M.-H., Yoo, C., Kim, J.G., et al. Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer. European Journal of Cancer 51 (2015), 482–488.
134. [134] Soularue, É., Cohen, R., Tournigand, C., et al. Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study. Bulletin du Cancer 102 (2015), 324–331.
135. [135] Hecht, J.R., Bang, Y.-J., Qin, S., et al. Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The TRIO-013/LOGiC Trial. Journal of Clinical Oncology, 31(Suppl), 2013 [abstr LBA4001]. Available at: http://meetinglibrary.asco.org/content/116873-132 [cite 17.04.15].
136. [136] Satoh, T., Xu, R.-H., Chung, H.C., et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN—a randomized, phase III study. Journal of Clinical Oncology 32 (2014), 2039–2049.
137. [137] Kang, Y.-K., Shah, M., Ohtsu, A., et al. A randomized, open-label, multicenter, adaptive phase 2/3 study of trastuzumab emtansine (T-DM1) versus a taxane (TAX) in patients (pts) with previously treated HER2-positive locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (LA/MGC/GEJC). Journal of Clinical Oncology, 34(Suppl), 2016 [abstr 5].
138. [138] Park, S.R., Park, Y.S., Ryu, M.-H., et al. Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: results of GASTric cancer HER2 reassessment study 1 (GASTHER1). European Journal of Cancer 53 (2016), 42–50.
139. [139] Oh, S.Y., Kwon, H.-C., Kim, S.-H., et al. Clinicopathologic significance of HIF-1alpha, p53, and VEGF expression and preoperative serum VEGF level in gastric cancer. BMC Cancer, 8, 2008, 123.
140. [140] Ohtsu, A., Shah, M.A., Van Cutsem, E., et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. Journal of Clinical Oncology 29 (2011), 3968–3976.
141. [141] Shen, L., Li, J., Xu, J., et al. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study). Gastric Cancer 18 (2015), 168–176.
142. [142] Wilke, H., Muro, K., Van Cutsem, E., et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncology 15 (2014), 1224–1235.
143. [143] Fuchs, C.S., Tomasek, J., Yong, C.J., et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383 (2014), 31–39.
144. [144] Lordick, F., Kang, Y.-K., Chung, H.-C., et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncology 14 (2013), 490–499.
145. [145] Waddell, T., Chau, I., Cunningham, D., et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncology 14 (2013), 481–489.
146. [146] Malka, D., Castan, F., François, E., et al. FOLFOX alone or combined to rilotumumab or panitumumab as first-line treatment in patients (pts) with advanced gastroesophageal adenocarcinoma (AGEA): an open-label, randomized phase II trial (PRODIGE 17 ACCORD 20 MEGA). Journal of Clinical Oncology, 33(Suppl), 2015 [abstr 4013].
147. [147] Cunningham, D., Tebbutt, N.C., Davidenko, I., et al. Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study. Journal of Clinical Oncology, 33(Suppl), 2015 [abstr 4000].
148. [148] Iveson, T., Donehower, R.C., Davidenko, I., et al. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study. Lancet Oncology 15 (2014), 1007–1018.
149. [149] Shah, M.A., Cho, J.Y., Huat, I.T.B., et al. Randomized phase II study of FOLFOX +/− MET inhibitor, onartuzumab (O), in advanced gastroesophageal adenocarcinoma (GEC). Journal of Clinical Oncology, 33(Suppl), 2015 http://hwmaint.meeting.ascopubs.org/cgi/content/abstract/33/3_suppl/2 [cite 19.04.15].
150. [150] Lennerz, J.K., Kwak, E.L., Ackerman, A., et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. Journal of Clinical Oncology 29 (2011), 4803–4810.
151. [151] Shah, M.A., Wainberg, Z.A., Catenacci, D.V.T., et al. Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. PLoS ONE, 8, 2013, e54014.
152. [152] Ohtsu, A., Ajani, J.A., Bai, Y.-X., et al. Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. Journal of Clinical Oncology 31 (2013), 3935–3943.
153. [153] Bang, Y.-J., Chung, H.-C., Shankaran, V., et al. Relationship between PD-L1 expression and clinical outcomes in patients with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in KEYNOTE-012. Journal of Clinical Oncology, 33(Suppl), 2015 [abstr 4001].
154. [154] Deng, N., Goh, L.K., Wang, H., et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 61 (2012), 673–684.
155. [155] Cancer Genome Atlas Research Network, Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513 (2014), 202–209.